Guanosine-specific cyclic nucleotide signaling is suggested to serve protective actions in the vasculature; however, the influence of selective pharmacologic modulation of cyclic guanosine monophosphatesynthesizing soluble guanylate cyclase or cyclic guanosine monophosphate-degrading phosphodiesterase on vessel remodeling has not been thoroughly examined. In this study, rat carotid artery balloon injury was performed and the growth-modulating effects of the soluble guanylate cyclase stimulator YC-1 or the cyclic guanosine monophosphate-dependent phosphodiesterase-V inhibitor zaprinast were examined. YC-1 or zaprinast elevated vessel cyclic guanosine monophosphate content, reduced medial wall and neointimal cell proliferation, stimulated medial and neointimal cellular apoptosis, and markedly attenuated neointimal remodeling in comparable fashion. Interestingly, soluble guanylate cyclase inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one failed to noticeably alter neointimal growth, and concomitant zaprinast with YC-1 did not modify any parameter compared to individual treatments. These results provide novel in vivo evidence that YC-1 and zaprinast inhibit injury-induced vascular remodeling through antimitogenic and proapoptotic actions and may offer promising therapeutic approaches against vasoproliferative disorders.
Introduction
The soluble guanylate cyclase (sGC)/cyclic guanosine monophosphate (GMP) signal transduction system plays an important regulatory role in the cardiovascular system. The vasoactive influence of sGC/cyclic GMP-stimulatory nitric oxide (NO) has been extensively studied and well characterized. More recently, our laboratory has helped identify the heme oxygenase (HO)/carbon monoxide (CO) system as a robust cyclic GMP-stimulating pathway following vascular injury. [1] [2] [3] Synthesized cyclic GMP exerts physiologic and pathophysiologic effects through multiple signaling pathways including direct activation of cyclic GMP-dependent protein kinase (PK-G), direct and/or indirect cross-talk with the cyclic adenosine monophosphate (AMP)/cyclic AMP-dependent protein kinase (PK-A) system, or hydrolytic degradation by cyclic GMP-dependent phosphodiesterase (PDE-V).
Based principally on its protective effects in cardiac and vascular tissues, much emphasis has been placed on identifying upstream pharmacologic activators or stimulators of the sGC/cyclic GMP system. YC-1 (3-(5 0 -hydroxymethyl-2 0 -furyl)-1-benzylindazole), originally characterized as a potent sGC activator in platelets, 4, 5 has been shown to protect against vascular smooth muscle injury through multiple growth-inhibitory properties. [6] [7] [8] [9] [10] In similar fashion, BAY 41-2272, a potent YC-1-based sGC stimulator, has been recently suggested to serve beneficial actions against aberrant vascular smooth muscle growth. 11 An alternate route for inducing salutary cyclic GMP signaling is through selective inhibition of cyclic GMP-degrading PDE, an approach successfully used to combat a variety of vascular disorders with perhaps the most popular being those used to treat sexual dysfunction. Zaprinast [1,4- 
, a selective inhibitor of cyclic GMP-specific PDE-V, significantly elevates cyclic GMP and downstream signaling in the vasculature. 12, 13 Several studies cite protective actions of zaprinast in hypoxic pulmonary vasculature, 14 during capillary leakage and edema, 15 or on platelet function following arterial injury, 16 whereas several others have shown beneficial effects of cyclic AMP-specific PDE-III inhibition on vessel growth [17] [18] [19] ; however, the influence of the PDE-V inhibitor zaprinast on the growth response to vascular injury is scientifically provocative yet has not been described in the literature.
Using YC-1 for comparison, the present study addressed the hypothesis that the selective cyclic GMP-dependent PDE-V inhibitor zaprinast attenuates remodeling in rat balloon-injured carotid arteries. Novel results demonstrate that both YC-1 and zaprinast elevate vessel cyclic GMP content, reduce vascular cell proliferation and stimulate apoptosis, and attenuate neointimal growth in similar manner. Furthermore, lack of significant 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ) and combined YC-1 and zaprinast effects suggest that YC-1 and zaprinast share common signaling pathways in the injury growth response and that these occur irrespective of upstream cyclase involvement.
Materials and Methods

Rat Carotid Artery Balloon Injury Model
Experimental balloon injury was performed on the rat left carotid artery (LCA) as described. 20 Briefly, male Sprague Dawley rats (520 + 10 g; Harlan, Indianapolis, Ind) were anesthetized (ketamine, xylazine, and acepromazine; 0.5-0.7 mL/kg intramuscular [IM]; VetMed Drugs) and a Fogarty 2F embolectomy catheter (Baxter Healthcare Corp, Deerfield, IL) was introduced through an external carotid arteriotomy site and advanced through the LCA, inflated, and withdrawn thrice. The exposed portion of the injured LCA was treated accordingly (see ''Dosing Protocol'' below), tissues were closed in layers, and animals were given buprenorphine (0.5 mg/kg, subcutaneous [SC]) for analgesia. At specific times, anesthetized rats were euthanized by pneumothorax and exsanguination and tissues were harvested for specific protocols. All procedures conformed to the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH Publication No 85-23, revised 1996) and were approved by the Institutional Animal Care and Use Committee (IACUC).
Dosing Protocol
Topical administration of pharmacologic agents immediately followed balloon injury. 6, 21 Two hundred microliters of a 25% copolymer gel solution (Pluronic F-127; BASF, Chicago, IL) containing 1 mg zaprinast (Calbiochem-Novabiochem Corp, La Jolla, CA), YC-1 (Calbiochem), or the specific sGC inhibitor ODQ (Calbiochem-Novabiochem Corp), or a combination thereof, in 50 mL dimethyl sulfoxide (DMSO) was administered to the exposed LCA adventitia. Control animals received 200 mL gel containing 50 mL DMSO. Animals were closed and allowed to recover until euthanasia.
Tissue Processing and Staining
Perfusion-fixed, paraffin-embedded tissues were used for standard staining techniques, and microscopic analysis and quantitation of morphologic parameters were performed. 21 Fresh tissues were snap frozen and used for the cyclic GMP assay. 6 
Cyclic GMP Radioimmunoassay
The protocol used for measuring cyclic GMP in vascular tissue followed that supplied with the 125 I-labeled cyclic GMP competitive radioimmunoassay (RIA) kit (Amersham Biosciences; GE Healthcare, Chalfont St. Giles, United Kingdom). 6 Forty-eight hours after injury animals were killed and fresh tissues were obtained and snap-frozen. Similarly treated tissues were pooled (n ¼ 3-5 animals/group) and the RIA was performed. Tissues were homogenized in cold 6% trichloroacetic acid, centrifuged, and the cyclic GMP-containing supernatant removed and ether washed. Cyclic GMP-containing extract was dried and resuspended in 200 mL assay buffer. Samples were acetylated and working standards were prepared. Sections of rat thoracic aorta were used as positive controls for cyclic GMP. 22 
Proliferating Cell Nuclear Antigen and TUNEL Assays
Immunostaining for proliferating cell nuclear antigen (PCNA) for estimating cell proliferation was performed on balloon-injured rat LCAs. 1 Tissues were treated with an anti-PCNA monoclonal antibody (PC-10; 1:25; Sigma-Aldrich, St. Louis, MO) complemented with a biotinylated anti-mouse secondary antibody (1:100), followed by an avidin-biotin block and diaminobenzidine (DAB) chromogen with nuclear fast red counterstain. Data are represented as a PCNA labeling index (LI), defined as the percentage of total cells positive for PCNA staining within a given area. 1 Rat balloon-injured LCAs were stained for apoptotic nuclei using an In Situ Cell Death Detection kit (Roche Applied Science, Indianapolis, IN) as described. 1 Tissues were treated with proteinase K, endogenous peroxidase activity was blocked, and tissues were exposed to avidin-biotin block with antigen retrieval. Tissues were incubated with TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) reaction mixture and treated with converter-peroxidase solution. Tissues were serially treated with DAB and hematoxylin. Data are represented as a TUNEL LI. Conventional light microscopy was performed on TUNEL-positive cells to confirm morphologic characteristics of apoptosis.
Statistical Analysis
Data were stored and analyzed on personal computers using Excel 2003 (Microsoft, United States), Sigma Plot 8.0 with Sigma Stat for Windows (v 3.0; SPSS, Inc, Chicago, IL), Instat (v 3.06; GraphPad Software Inc, La Jolla, CA), and Origin 7 SR1 (v 7.0; OriginLab Corporation, Northhampton, MA). Data were grouped according to treatment and analyzed using a 1-way ANOVA with post hoc Holm-Sidak test for pairwise comparisons. All data are represented as mean + standard error of the mean (SEM). A P value <.05 is considered statistically significant for all comparisons.
Results
Rat Carotid Artery Balloon Injury Model
Representative photomicrographs of rat balloon-injured LCAs 14 days postinjury are shown in Figure 1 . An injured LCA treated with empty hydrogel ( Figure 1A ) exhibits a concentric and significant neointima with a clearly defined medial wall and elastic laminae. Figure 1B shows an injured zaprinast-treated LCA with a significantly attenuated neointima, appearing sporadically as a thin nonconcentric layer adjacent to the internal lamina. Figure 1C illustrates an injured YC-1-treated LCA and similarly shows reduced neointimal development. Figure 1D shows an injured LCA treated with combined zaprinast and YC-1, and a significantly diminished neointima is observed yet no additive effect is seen compared to individual zaprinast-or YC-1-treated sections. Figure 1E shows an ODQ-treated vessel with a significant and concentric neointima (similar to controls), whereas Figure 1F shows an ODQ and YC-1-treated vessel. Corresponding histomorphometric data obtained 14 days postinjury are shown in Figure 2 . Figures 2A, 2C , and 2D clearly show significant and comparable attenuation of neointimal growth in injured LCAs treated with zaprinast, YC-1, or zaprinast plus YC-1 compared to vehicle controls. Separate cohorts of injured arteries treated with ODQ failed to show observable changes in neointima formation relative to vehicle controls, and arteries exposed to combined ODQ and YC-1 failed to fully reverse the YC-1-inhibitory effects on neointimal growth. Interestingly, LCAs exposed to zaprinast, either alone or in combination with YC-1, displayed significant medial wall enlargement compared to vehicle controls ( Figure 2B ). Analyses of the circumferences of LCA internal and external elastic laminae between all treatment groups revealed no significant differences after 14 days (data not shown). 
Cyclic GMP
Zaprinast stimulated a significant 2.7-fold increase in cyclic GMP content in injured LCAs compared to injured vehicle controls (61.61 + 5.62 vs 23.04 + 2.30 fmol/mg protein, respectively) 48 hours postinjury. At this time, YC-1 also markedly elevated vessel cyclic GMP levels compared to controls (35.45 + 2.2 vs 22.12 + 4.3 fmol/mg protein, respectively), substantiating previously observed findings. 6 Interestingly, combined zaprinast and YC-1 failed to increase cyclic GMP over that observed in the zaprinast-only treated group (63.66 + 3.12 vs 61.61 + 5.62 fmol/mg protein, respectively). Rat balloon-injured LCAs exposed to empty hydrogel (vehicle controls) did not demonstrate altered cyclic GMP compared to untreated injured sections, and uninjured LCAs treated with zaprinast and/or YC-1 did not show changes in cyclic GMP levels compared to uninjured untreated sections (data not shown).
Proliferating Cell Nuclear Antigen and TUNEL
Temporal analyses of vessel wall DNA replication, performed by PCNA immunostaining, were performed 1, 2, 7, and 14 days following injury (Figure 3 ). Data show markedly reduced PCNA staining in zaprinastand YC-1-treated groups in both the medial wall ( Figure 3A Figure 4 illustrates results from TUNEL immunostaining for LCA medial and neointimal cell apoptosis 14 days postinjury. Marked proapoptotic effects from zaprinast or YC-1 are clearly evident. Vessel wall TUNEL results at 1, 2, and 7 days postinjury revealed no specific trend for apoptosis (data not shown). TUNEL-positive cells consistently exhibited marked cellular contraction, nuclear condensation, and intracellular cytoplasmic blebbing observed via light microscopy by an independent observer (data not shown).
Discussion
The current study shows for the first time that the selective cyclic GMP-dependent PDE-V inhibitor zaprinast confers protection against vascular growth following experimental injury. In the rat carotid artery balloon injury model, perioperative zaprinast significantly elevated vessel cyclic GMP levels and markedly inhibited neointimal growth through antiproliferative and proapoptotic avenues. Analogous effects were observed with the sGC stimulator YC-1, and combined YC-1 with zaprinast failed to show discernable effects over individual treatments, thus suggesting that these agents operate via similar signaling pathways. Moreover, cyclase inhibition by ODQ failed to exert demonstrable impact on vessel growth, implying that these phenomena occur in sGC-independent fashion. Indeed, these provocative results offer in vivo insights into the mechanisms of action of these upstream and downstream cyclic GMP modulators and suggest promising therapeutic approaches for the treatment of vascular proliferative disorders.
In this study, zaprinast significantly elevated cyclic GMP in injured arteries in the same range as that reported in rat primary vascular smooth muscle following growth factor stimulation 23 and in rat cardiac tissue after natriuretic peptide stimulation. 24 We observed that YC-1 also increased vessel cyclic GMP after injury, substantiating earlier results in this same model 6 and in a separate study using rat primary vascular smooth muscle cells. 7 These results support bioactivity of cyclic GMP signaling by zaprinast and YC-1 in this experimental in vivo model. Interestingly, in this study concomitant zaprinast with YC-1 failed to induce cyclic GMP over that observed with zaprinast alone, suggesting common pathways exist for these agents in this experimental setting. This is highly plausible considering that YC-1 exerts potent (IC 50 half maximal inhibitory concentration ¼ 10 mmol/L) PDE-V inhibition in addition to its well-documented cyclase-stimulatory actions. 25, 26 These remarkable results suggest that YC-1 may operate primarily through downstream PDE-V inhibition in vascular tissues following trauma. A recent article showing that YC-1 attenuates homotypic neutrophil aggregation primarily through inhibition of PDE activity 27 supports this theory. Conversely, these findings may also infer that sGC is fully activated in the zaprinast-treated injured vessel and is therefore unable to synthesize additional cyclic GMP in the presence of a stimulatory agonist such as YC-1.
Vascular growth is largely dependent on a balance between tissue gain and loss, critical parameters for therapeutic targeting. Zaprinast or YC-1 significantly and equally attenuated injury-induced neointimal growth in the rat carotid artery (Figures 1 and 2 ), suggesting that these agents operate via similar mechanisms in their growth-reducing effects. Conversely, these findings may also suggest that growth inhibition from these compounds is maximal and has reached a plateau and that further reduction in growth via additive, synergistic, or potentiative avenues is not possible under these experimental conditions. Further study is warranted with these promising agents, perhaps at lower doses than those used in the current investigation, to address this possibility. Interestingly, zaprinast, alone or in conjunction with YC-1, resulted in medial wall enlargement in addition to its attenuating effects on neointimal formation. This is an apparent paradox, considering that zaprinast significantly inhibited medial cell DNA and cellular replication and stimulated medial cell apoptosis, processes that eventuate in loss of medial wall architecture and integrity. Current investigations into potential mechanisms that could contribute to an enlarged medial area from zaprinast, which may include directional cell migration, altered production of extracellular matrix (ECM) components, or changes in ECM-degrading metalloproteinases (MMPs), should prove insightful and may offer potential underlying mechanisms.
The inhibitory effects of zaprinast on vascular DNA replication and cellularity observed in this study support recent reports of the cytostatic actions of zaprinast on cells of different origins. [28] [29] [30] We now provide first evidence that zaprinast can directly reduce proliferation of vascular cells following experimental injury. Zaprinast has been found to potentiate NO-mediated apoptosis in megakaryocytes 31 and natriuretic peptide-induced apoptosis in rat cardiac myocytes 32 and pulmonary endothelium, 30 although zaprinast itself has been suggested to lack apoptotic capacity. 33 Considering earlier results showing that balloon injury upregulated sGC-sensitizing NO synthase and HO enzymes, 6 herein we provide novel data showing potent proapoptotic effects of zaprinast in vascular tissues after injury. The proapoptotic effects of YC-1 observed in this report corroborate previous findings that YC-1 stimulates apoptosis in neutrophils 34 and in adrenomedullary endothelial and chromaffin cells, 35 possibly through caspase-3-like protease activity in fashion independent of sGC. 35 A recent article provides strong evidence that cyclic GMP/PK-G signaling is not involved in the protective effects of NO during vascular remodeling. 36 Experiments using ODQ in the current report suggest that sGC is not involved in zaprinast-or YC-1-mediated vascular growth inhibition, yet cumulative findings also suggest that zaprinast and YC-1 share common signaling pathways, that is, through inhibition of cyclic GMP-degrading PDE-V with ensuing cyclic GMP-dependent actions. Differences in experimental models (arterial ligation or wire denudation vs balloon distension) and species (mouse versus rat) as well as distinct upstream activating ligands (NO versus CO) must be considered when comparing such studies.
Conclusions
Herein, we demonstrate that the cyclic GMP-dependent PDE-V inhibitor zaprinast provides protection against vessel growth after injury through inhibition of vascular cell proliferation and induction of apoptosis. Analogous results with the sGC stimulator YC-1 suggest that YC-1 and zaprinast operate through parallel pathways in the vascular growth response following trauma. In addition, lack of noticeable effects from concomitant YC-1 and zaprinast suggest that these agents operate in sGC-independent fashion under these experimental conditions. This new evidence provides insights into the mechanisms and potential therapeutic applicability of the cyclic GMP modulators YC-1 and zaprinast for the treatment of vasculoproliferative disorders.
